Nice work, thanks for the link. What we investors in Elite need to remember is that we did not invest in the company because of Isradipine's potential. Most invested in the ADFs platform and drug potential, but are happier with the movement toward a truly diversified portfolio that includes the CNS drugs that have a real opportunity to capture notable market share. In fact, the entire set of non-ADF drugs offer a return that makes me indifferent to the ADFs and the answer is simple...risk reduction. Not pursuing the ADF opioids right now means staying on the litigation sidelines and not spending money, while allowing the CNS drugs to move the needle and, ultimately, offer the means to fund other trials needed. It is not that I would suggest shelving the IR ADFs, but they are a timing issue; as I see it.
In the meantime, we await FDA news. And, what I hope was not missed as an important factor was the FDA reviews of Elite's manufacturing plant without issue. A key point to ensuring the ability to commercialize as soon as possible upon approval. All too many companies get approval and find the plant set to manufacture has been beset by FDA issues, putting the commercialization behind. One more point about the fact that Elite has its own plant is that it controls costs more effectively than if they contracted manufacturing. For a generic company, cost is key to the operational strategy. Any doubts, check WMT...MCD...LUV...cost strategies one and all. Teva is the biggest generic drug producer but has run into cost issues that have contributed to its current problems.
News 
Market Data 
Discover 
